🚀 VC round data is live in beta, check it out!
Armata Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Armata Pharmaceuticals and similar public comparables like AIM Vaccine, Lineage Cell Therapeutics, Rocket Pharmaceuticals, Autolus Therapeutics and more.
Armata Pharmaceuticals Overview
About Armata Pharmaceuticals
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Founded
1989
HQ
Employees
60
Website
Sectors
Financials (LTM)
EV
$701M
Armata Pharmaceuticals Financials
Armata Pharmaceuticals reported last 12-month revenue of $3M and negative EBITDA of ($31M).
In the same LTM period, Armata Pharmaceuticals generated $3M in gross profit, ($31M) in EBITDA losses, and had net loss of ($142M).
Revenue (LTM)
Armata Pharmaceuticals P&L
In the most recent fiscal year, Armata Pharmaceuticals reported revenue of $5M and EBITDA of ($31M).
Armata Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3M | XXX | $5M | XXX | XXX | XXX |
| Gross Profit | $3M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($31M) | XXX | ($31M) | XXX | XXX | XXX |
| EBITDA Margin | (904%) | XXX | (634%) | XXX | XXX | XXX |
| EBIT Margin | (1163%) | XXX | (637%) | XXX | XXX | XXX |
| Net Profit | ($142M) | XXX | ($174M) | XXX | XXX | XXX |
| Net Margin | (4123%) | XXX | (3544%) | XXX | XXX | XXX |
| Net Debt | — | — | $248M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Armata Pharmaceuticals Stock Performance
Armata Pharmaceuticals has current market cap of $421M, and enterprise value of $701M.
Market Cap Evolution
Armata Pharmaceuticals' stock price is $11.50.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $701M | $421M | 0.0% | XXX | XXX | XXX | $-4.74 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialArmata Pharmaceuticals Valuation Multiples
Armata Pharmaceuticals trades at 203.7x EV/Revenue multiple, and (22.5x) EV/EBITDA.
EV / Revenue (LTM)
Armata Pharmaceuticals Financial Valuation Multiples
As of April 19, 2026, Armata Pharmaceuticals has market cap of $421M and EV of $701M.
Equity research analysts estimate Armata Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Armata Pharmaceuticals has a P/E ratio of (3.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $421M | XXX | $421M | XXX | XXX | XXX |
| EV (current) | $701M | XXX | $701M | XXX | XXX | XXX |
| EV/Revenue | 203.7x | XXX | 142.9x | XXX | XXX | XXX |
| EV/EBITDA | (22.5x) | XXX | (22.5x) | XXX | XXX | XXX |
| EV/EBIT | (17.5x) | XXX | (22.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 203.7x | XXX | — | XXX | XXX | XXX |
| P/E | (3.0x) | XXX | (2.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (26.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Armata Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Armata Pharmaceuticals Margins & Growth Rates
Armata Pharmaceuticals' revenue in the last 12 month declined by (100%).
Armata Pharmaceuticals' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.5M for the same period.
Armata Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (100%) | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | (904%) | XXX | (634%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 2173% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 358% | XXX | 253% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 782% | XXX | 484% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 637% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Armata Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| AIM Vaccine | XXX | XXX | XXX | XXX | XXX | XXX |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Rocket Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Autolus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Recbio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Armata Pharmaceuticals M&A Activity
Armata Pharmaceuticals acquired XXX companies to date.
Last acquisition by Armata Pharmaceuticals was on XXXXXXXX, XXXXX. Armata Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Armata Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialArmata Pharmaceuticals Investment Activity
Armata Pharmaceuticals invested in XXX companies to date.
Armata Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Armata Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Armata Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Armata Pharmaceuticals
| When was Armata Pharmaceuticals founded? | Armata Pharmaceuticals was founded in 1989. |
| Where is Armata Pharmaceuticals headquartered? | Armata Pharmaceuticals is headquartered in United States. |
| How many employees does Armata Pharmaceuticals have? | As of today, Armata Pharmaceuticals has over 60 employees. |
| Who is the CEO of Armata Pharmaceuticals? | Armata Pharmaceuticals' CEO is Deborah L. Birx. |
| Is Armata Pharmaceuticals publicly listed? | Yes, Armata Pharmaceuticals is a public company listed on NYSE American. |
| What is the stock symbol of Armata Pharmaceuticals? | Armata Pharmaceuticals trades under ARMP ticker. |
| When did Armata Pharmaceuticals go public? | Armata Pharmaceuticals went public in 1994. |
| Who are competitors of Armata Pharmaceuticals? | Armata Pharmaceuticals main competitors are AIM Vaccine, Lineage Cell Therapeutics, Rocket Pharmaceuticals, Autolus Therapeutics. |
| What is the current market cap of Armata Pharmaceuticals? | Armata Pharmaceuticals' current market cap is $421M. |
| What is the current revenue of Armata Pharmaceuticals? | Armata Pharmaceuticals' last 12 months revenue is $3M. |
| What is the current revenue growth of Armata Pharmaceuticals? | Armata Pharmaceuticals revenue growth (NTM/LTM) is (100%). |
| What is the current EV/Revenue multiple of Armata Pharmaceuticals? | Current revenue multiple of Armata Pharmaceuticals is 203.7x. |
| Is Armata Pharmaceuticals profitable? | No, Armata Pharmaceuticals is not profitable. |
| What is the current EBITDA of Armata Pharmaceuticals? | Armata Pharmaceuticals has negative EBITDA and is not profitable. |
| What is Armata Pharmaceuticals' EBITDA margin? | Armata Pharmaceuticals' last 12 months EBITDA margin is (904%). |
| What is the current EV/EBITDA multiple of Armata Pharmaceuticals? | Current EBITDA multiple of Armata Pharmaceuticals is (22.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.